Johnson & Johnson (JNJ) vs Vanguard S&P 500 ETF (VOO)
See how Johnson & Johnson and Vanguard S&P 500 ETF differ across market data and performance, so you can decide which asset best fits your strategy.
$253.04
NYSE
Johnson & Johnson is the world’s largest and most diversified healthcare company. Its operations are organized into two segments: Innovative Medicine and MedTech, which together account for all revenue following the 2023 separation of its consumer health business, Kenvue. After restructurings completed in 2023 and 2024, the pharmaceutical segment is focused on three core therapeutic areas: immunology, oncology, and neurology. From a geographic perspective, slightly more than half of the company’s total revenue comes from the United States.
Vanguard S&P 500 ETF is an exchange-traded fund that gives investors diversified exposure to large-cap U.S. companies in the S&P 500 Index. It is designed to track or represent a basket of publicly traded securities rather than a single company, making it useful for portfolio allocation, regional exposure, and thematic positioning. Its performance depends on the underlying holdings, sector and country weights, currency movements where relevant, fund expenses, and broader equity-market conditions.